[{"orgOrder":0,"company":"Biocodex","sponsor":"PANTHERx Rare Pharmacy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PANTHERx Rare Announces Partnership with Biocodex for the Distribution of DIACOMIT\u00ae (stiripentol) for the Treatment of Seizures Associated with Dravet Syndrome in Patients 2 Years of Age and Older Taking Clobazam","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"Stiripentol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biocodex","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ PANTHERx Rare","highestDevelopmentStatusID":"12","companyTruncated":"Biocodex \/.."},{"orgOrder":0,"company":"Biocodex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antiseizure Drug DIACOMIT Now Approved for Children as Young as 6 Months","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Stiripentol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biocodex","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocodex \/.."}]

Find Clinical Drug Pipeline Developments & Deals for DSSTox_CID_28994

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : DIACOMIT (stiripentol) is an effective treatment for seizures that are often resistant to other antiepileptic drugs. In two clinical studies, DIACOMIT reduced generalized clonic or tonic-clonic seizures by a median of 84% compared with 5.8% on placebo af...

                          Brand Name : Diacomit

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 21, 2022

                          Lead Product(s) : Stiripentol

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : DIACOMIT (stiripentol), is a molecular entity approved by the FDA for the adjunctive treatment of seizures associated with Dravet syndrome in 2 years of age and older taking clobazam. An orally administered, DIACOMIT is given as either a capsule or powde...

                          Brand Name : Diacomit

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 27, 2022

                          Lead Product(s) : Stiripentol

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : PANTHERx Rare Pharmacy

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank
                          Close
                          4